SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Andersen Stig U.) "

Sökning: WFRF:(Andersen Stig U.)

  • Resultat 1-4 av 4
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • 2019
  • Tidskriftsartikel (refereegranskat)
  •  
3.
  •  
4.
  • Gimsing, P, et al. (författare)
  • Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
  • 2015
  • Ingår i: Bone Marrow Transplantation. - : Springer Science and Business Media LLC. - 1476-5365 .- 0268-3369. ; 50:10, s. 1306-1311
  • Tidskriftsartikel (refereegranskat)abstract
    • Until recently, only retrospective studies had been published on salvage high-dose melphalan (HDM) with autologous stem cell 'transplantation' (ASCT). In a prospective, nonrandomized phase-2 study, we treated 53 bortezomib-naïve patients with bortezomib-dexamethasone as induction and bortezomib included in the conditioning regimen along with the HDM. Median progression-free survival (PFS), time to next treatment (TNT) and overall survival (OS) after start of reinduction therapy were 21.6, 22.8 and 46.6 months, respectively. For 49 patients who completed salvage bortezomib-HDM(II) with ASCT, there was no significant difference of PFS and TNT after HDM (II) compared with after the initial HDM(I), and thus patients were their own controls (PFS (I: 20.1 vs II: 19.3 months (P=0.8)) or TNT (I: 24.4 vs II: 20.7 months (P=0.8)). No significant differences in the response rates after salvage ASCT compared with the initial ASCT. Bortezomib-HDM conditioning combo was feasible, and toxicity was as expected for patients treated with bortezomib and ASCT. In conclusion, in bortezomib-naïve patients treated at first relapse with salvage ASCT including bortezomib, PSF and TNT did not differ significantly from initial ASCT and median OS was almost 5.5 years with acceptable toxicity. A recent prospective randomized study confirms salvage ASCT to be an effective treatment.Bone Marrow Transplantation advance online publication, 29 June 2015; doi:10.1038/bmt.2015.125.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-4 av 4
Typ av publikation
tidskriftsartikel (3)
konferensbidrag (1)
Typ av innehåll
refereegranskat (4)
Författare/redaktör
Lenhoff, Stig (2)
Zhang, Yan (1)
Korhonen, Laura (1)
Lindholm, Dan (1)
Kelly, Daniel (1)
Vertessy, Beata G. (1)
visa fler...
Bengtsson-Palme, Joh ... (1)
Nilsson, Henrik (1)
Kelly, Ryan (1)
Li, Ying (1)
Moore, Matthew D. (1)
Wang, Mei (1)
Wang, Xin (1)
Liu, Yang (1)
Zhang, Yang (1)
Kumar, Rakesh (1)
Wang, Dong (1)
Liu, Fang (1)
Li, Ke (1)
Liu, Ke (1)
Zhang, Yao (1)
Jin, Yi (1)
Raza, Ali (1)
Rafiq, Muhammad (1)
Zhang, Kai (1)
Khatlani, T (1)
Nàgy, Péter (1)
Kahan, Thomas (1)
Kominami, Eiki (1)
van der Goot, F. Gis ... (1)
Sörelius, Karl, 1981 ... (1)
Bonaldo, Paolo (1)
Batra, Jyotsna (1)
Roobol, Monique J (1)
Adams, Christopher M (1)
Minucci, Saverio (1)
Vellenga, Edo (1)
Backman, Lars (1)
Yan, Hong (1)
Swärd, Karl (1)
Nilsson, Per (1)
Schmidt, Axel (1)
Lorkowski, Stefan (1)
Thrift, Amanda G. (1)
De Milito, Angelo (1)
Zhang, Wei (1)
Zhang, Jian (1)
Hammerschmidt, Sven (1)
Patil, Chandrashekha ... (1)
Shukla, Deepak (1)
visa färre...
Lärosäte
Lunds universitet (4)
Stockholms universitet (2)
Karolinska Institutet (2)
Göteborgs universitet (1)
Umeå universitet (1)
Uppsala universitet (1)
visa fler...
Högskolan i Halmstad (1)
Linköpings universitet (1)
Chalmers tekniska högskola (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (4)
Naturvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy